-
Analyst On La Jolla's Hypotension Drug: We Expect Approval Next Year
Monday, May 22, 2017 - 11:23am | 611Read More...Following the publication of full data from a late-stage study of La Jolla Pharmaceutical Company (NASDAQ: LJPC)'s LPJC-501, a proprietary formulation of angiotensin II, SunTrust Robinson Humphrey said it expects approval in 2018. The Study And The Results The full data from the Phase III study,...
-
La Jolla Meets ATHOS-3 Trial Endpoints, Dispels Market Controversy In The Process
Monday, May 22, 2017 - 9:34am | 366Read More...Shares of La Jolla Pharmaceutical Company (NASDAQ: LJPC) were trading lower by more than 8 percent Monday morning after the company released Phase 3 results in the New England Journal of Medicine from a study called ATHOS-3, which evaluated the company's therapy LJPC-501 for the treatment of...
-
Hyperactivity In La Jolla Pharma Shares As Hypotension Treatment Aces Late-Stage Trial
Monday, February 27, 2017 - 5:07pm | 490Read More...The capriciousness associated with the biotech space is in the forefront once again with the near doubling in the shares of La Jolla Pharmaceutical Company (NASDAQ: LJPC) on Monday. The shares were on a high in reaction to positive trial results of its treatment option for hypotension. The...
-
Accenture, Covidien, Seagate and Other St. Patrick's Stock Picks
Friday, March 16, 2012 - 6:49am | 1019Read More...St. Patrick's Day is almost upon us. So here is a quick look at how the stocks of some companies headquartered in Ireland are faring, given the uncertain economic situation in Europe. Accenture's (NYSE: ACN) share price is up more than 17% year to date, including a 9% surge in the past month. The...
